---
company: Sotera Health Co
ticker: SHC
form: 8-K
filed: 2026-08-06
accession: 0001822479-26-000044
source: https://www.sec.gov/Archives/edgar/data/1822479/000182247926000044/
---

# Sotera Health (SHC) earnings release, August 6, 2026

Sotera Health Co (SHC) · Form 8-K, Item 2.02 · Filed 2026-08-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1822479/000182247926000044/)

Sotera Health Delivers Strong Second-Quarter and

First-Half 2026 Results and Raises FY 2026 Outlook

• Q2 2026 net revenues increased 9.2% or 8.0% on a constant currency basis

(1) compared to Q2 2025

• Q2 2026 net income of $54 million or $0.19 per diluted share, compared to net income of $8 million or $0.03 per diluted share in Q2 2025

• Q2 2026 Adjusted EBITDA

(1) increased 10.0%, or 8.7% on a constant currency basis

• Q2 2026 Adjusted EPS

(1) of $0.26, an increase of 30% per diluted share

• Company raises both full-year 2026 net revenues growth outlook to 5.25% - 6.75% and Adjusted EBITDA growth outlook to 5.75% - 7.25%, on a constant currency basis

CLEVELAND, OH, August 6, 2026 – Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and six- months ended June 30, 2026.

“We delivered another strong quarter, with high-single-digit growth, reflecting focused execution across all three of our business units,” said Chief Executive Officer Alton Shader. “These results further underscore the essential nature of Sotera Health’s offerings to healthcare. Since joining the Company, I have been impressed by the dedication of our teams, the trust our customers place in us and the industry-leading expertise that differentiates our business in highly regulated healthcare markets. Together, these strengths position us well to deliver consistent and reliable growth.”

Shader continued, “Based on our strong first-half performance and confidence in the remainder of the year, we are raising our full-year 2026 outlook. I am excited about the numerous opportunities we have for growth as we continue to deepen our customer relationships, invest in our people, facilities and capabilities, and execute on our long-term strategy.”

Second-Quarter 2026 Highlights

(All comparisons are against second quarter of 2025, unless otherwise noted)

• Delivered strong, high-single-digit top- and bottom-line constant currency growth

• Expanded Adjusted EBITDA margin

(1) to 51.6%

• Sterigenics: 7.0% constant currency revenue growth; segment income margin improvement of 53 basis points

• Nordion: 16.7% constant currency revenue growth; segment income margin improvement of 160 basis points

• Nelson Labs: 5.4% constant currency revenue growth; sequential segment income margin improvement of 438 basis points

• Net cash provided by operating activities of $88 million

• June 30, 2026, Net Leverage Ratio

(1) of 3.0x; achieved long-term target range of 2.0x to 3.0x; available liquidity of approximately $950 million

(1)

This is a non-GAAP financial measure used throughout this press release; please refer to the section “Non-GAAP Financial Measures” for explanations of our non-GAAP financial measures and the schedules provided later in this release for reconciliations of reported GAAP to non-GAAP financial measures.

• Repriced term loan, saving approximately $3.5 million of annual interest expense

• Completed final private equity sponsor secondary offering, with no remaining sponsor ownership

Second-Quarter and First-Half 2026 Review by Business Segment

(All comparisons are against second quarter of 2025, unless otherwise noted)

Sterigenics

Sterigenics delivered strong second-quarter 2026 results, with net revenues up 8.6% to $212 million, or 7.0% on a constant currency basis. Segment income improved to $118 million, an increase of 9.6%. For the first six months of 2026, Sterigenics net revenues increased 9.1% to $398 million, or 6.6% on a constant currency basis. Segment income increased 9.6% to $215 million.

Second-quarter net revenues growth was driven by favorable pricing, improved volume/mix and a foreign currency benefit. Segment income and segment income margin also benefited from these factors, partially offset by inflation.

Nordion

Nordion net revenues were up 15.8% to $49 million, or 16.7% on a constant currency basis while segment income increased 19.2% to $28 million. For the first six months of 2026, Nordion net revenues increased 21.6% to $91 million, or 20.8% on a constant currency basis. Segment income increased 26.4% to $52 million.

Second-quarter net revenues growth was driven by improved volume/mix, primarily due to the timing of Cobalt-60 harvests and favorable pricing, partially offset by foreign currency. Segment income and segment income margin also benefited from these factors, partially offset by inflation.

Nelson Labs

Nelson Labs delivered strong second-quarter net revenues growth of 6.3% to $61 million, or 5.4% on a constant currency basis. Segment income improved to $20 million, an increase of 0.6%. For the first six months of 2026, Nelson Labs net revenues improved 2.9% to $113 million, or 0.9% on a constant currency basis, while segment income decreased 4.9% to $34 million.

Second-quarter net revenues and segment income growth were driven by favorable pricing, improved volume/mix and a foreign currency benefit. Segment income margin was impacted by higher costs.

Balance Sheet and Liquidity

As of June 30, 2026, Sotera Health had $2.2 billion of total debt, and $357 million in unrestricted cash and cash equivalents, compared to $2.2 billion in total debt and $345 million in unrestricted cash and cash equivalents as of December 31, 2025. Sotera Health’s Net Leverage Ratio as of June 30, 2026 improved to 3.0x, achieving the Company’s long-term net leverage ratio target range of 2.0x to 3.0x. As of June 30, 2026, available liquidity increased to approximately $950 million, and the Company had no outstanding borrowings under its $600 million revolving credit facility.²

Full-Year 2026 Outlook

Today, Sotera Health is raising its 2026 outlook:

• ... (truncated)estimated 100 basis points of foreign currency benefit

• Adjusted EBITDA range raised to $634 million to $643 million, representing constant currency growth of 5.75% to 7.25% and an estimated 100 basis points of foreign currency benefit

• Interest expense improved to a range of $135 million to $142 million

• Tax rate applicable to Adjusted Net Income

(1) improved to a range of 27.0% to 28.0%

• Adjusted EPS improved to a range of $0.95 to $1.01

• A weighted-average fully diluted share count in the range of 289 million to 291 million shares

• Capital expenditures in the range of $200 million to $225 million

The Company does not provide a reconciliation for non-GAAP financial measures on a forward-looking basis where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items without unreasonable effort. The Company cannot reconcile its expected Adjusted EBITDA,

Tax Rate Applicable to Adjusted Net Income, Adjusted Net Income and Adjusted EPS without unreasonable effort because certain items that impact net income, earnings per share and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time, including uncertainties caused by changes to the regulatory landscape, restructuring items and certain fair value measurements, all of which are potential adjustments for future earnings.

The outlook provided above contains a number of assumptions, including, among others, the Company’s current expectations regarding supply chain continuity, particularly for the supply of ethylene oxide (“EO”) and Cobalt-60, and the impact of inflationary trends, including their impact on energy prices and the supply of labor. Our outlook is based on current plans and expectations and is subject to several known and unknown risks and uncertainties, including those set forth below under “Cautionary Note Regarding Forward-Looking Statements.”

Earnings Webcast

Sotera Health management will host a conference call and live webcast to discuss the Company’s operating highlights and financial results at 9:00 a.m. Eastern Daylight Time today. A live webcast of the conference call will be accessible at this link or via the Investor Relations section of the Company’s website at

Presentation & Events | Sotera Health, along with accompanying materials. A replay of the webcast will be archived on the Company’s website.

Upcoming Investor Events

• Wells Fargo 21st Annual Healthcare Conference at 1:30 p.m. Eastern Daylight Time, September 9, 2026

Cautionary Note Regarding Forward-Looking Statements

Unless expressly indicated or the context requires otherwise, the terms “Sotera Health,” “Company,” “we,” “us,” and “our” in this release refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and reflects management’s expectations about future events and the Company’s operating plans and performance and speak only as of the date hereof. Forward-looking statements present our current forecasts and estimates of future events. These statements do not strictly relate to historical or current results and can be identified by words such as “anticipate,” “appear,” “assume,” “believe,” “estimate,” “expect,”

(1)

This is a non-GAAP financial measure used throughout this press release; please refer to the section “Non-GAAP Financial Measures” for explanations of our non-GAAP financial measures.³

“forecast,” “intend,” “likely,” “may,” “plan,” “project,” “seek,” “should,” “strategy,” “will” and other terms of similar meaning or import in connection with any discussion of future operating, financial or other performance. These forward-looking statements are subject to risks, uncertainties and other factors and actual results may differ materially from those results projected in the statements. These forward-looking statements are subject to various risks, uncertainties and assumptions relating to our operations, financial results, financial condition, business, prospects, growth strategy and liquidity. These risks and uncertainties include, but are not limited to, a disruption in the availability or supply of, or increases in the price of, EO, Co-60 or our other direct materials, services and supplies, including as a result of geopolitical instability and/or sanctions against Russia by the United States, Canada, the United Kingdom and/or the European Union, or sanctions by Russia against those countries; fluctuations in foreign currency exchange rates; evolving changes in environmental, health and safety regulations; health and safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials such as EO and Co-60; the impact and outcome of current and future legal proceedings and liability claims, including litigation related to the use, emissions and releases of EO from our current and former EO sterilization facilities, and the possibility that additional claims will be made in the future; allegations of our failure to properly perform services and potential product liability claims, recalls, penalties and reputational harm; compliance with the extensive regulatory requirements to which we are subject, the related costs, and any failures to receive or maintain, or delays in receiving, required clearances or approvals; adverse changes in industry trends; competition we face; market conditions and changes, including inflationary trends and the impact of tariffs, that impact our long-term supply contracts with variable price clauses and increase our cost of revenues; business continuity hazards, including supply chain disruptions, federal government shutdowns, and other risks associated with our operations; the risks of doing business internationally, including global and regional economic and political instability and compliance with various applicable laws and potentially inconsistent laws and regulations in multiple jurisdictions; our ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner and renew leases for our leased facilities; our ability to attract and retain qualified employees; severe health events or environmental events; cybersecurity incidents, unauthorized data disclosures, and our dependence on information technology systems; the risks associated with the introduction of artificial intelligence technology; an inability to pursue strategic transactions, find suitable acquisition targets, or integrate strategic acquisitions into our business successfully; our ability to maintain effective internal control over financial reporting; our reliance on intellectual property rights to maintain our competitive position and the risk of claims from third parties that we have infringed or misappropriated, or are infringing or misappropriating, their intellectual property rights; our ability to comply with rapidly evolving data privacy and security laws and regulations in various jurisdictions and any ineffective compliance efforts with such laws and regulations; our ability to generate profitability in future periods; impairment charges on our goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives; the effects of unionization efforts and labor regulations in countries in which we operate; adverse changes to our tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of U.S. tax legislation or other changes in U.S. or non-U.S. taxation of our operations; and our significant degree of leverage and how this leverage could adversely affect our ability to raise additional capital, limit our ability to react to challenges facing our Company or broader changes in our industry or the economy, limit our flexibility in operating our business through restrictions contained in our debt agreements and/or prevent us from meeting our obligations under our existing and future agreements governing our indebtedness. For additional discussion of these risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, such as its Annual Report on Form 10-K and quarterly reports. We do not undertake any obligation to publicly update or revise these forward-looking statements, except as otherwise required by law.

Non-GAAP Financial Measures

To supplement our consolidated financial statements presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), we consider Adjusted EBITDA, Adjusted EBITDA margin, Tax Rate Applicable to Adjusted Net Income, Adjusted Net Income, Adjusted EPS, Net Debt, Net Leverage Ratio and constant currency, each of which is a financial measure not based on any standardized methodology prescribed by GAAP.⁴

• We define Adjusted Net Income as net income (loss) before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period.

• We define Adjusted EBITDA as Adjusted Net Income before interest expense, depreciation (including depreciation of Cobalt-60 used in our operations) and income tax provision applicable to Adjusted Net Income.

• Adjusted EBITDA margin is equal to Adjusted EBITDA divided by net revenues.

• We define Adjusted EPS as Adjusted Net Income divided by the weighted average number of diluted shares outstanding.

• Our Net Debt is equal to our total debt, net of unamortized debt issuance costs and debt discounts, less cash and cash equivalents.

• Our Net Leverage Ratio is equal to Net Debt divided by Adjusted EBITDA.

• Tax Rate Applicable to Adjusted Net Income represents the difference between the income tax provision as determined under U.S. GAAP and the income tax benefit/provision associated with pre-tax adjustments used to calculate Adjusted Net Income.

Constant currency is a non-GAAP financial measure we use to assess performance excluding the impact of foreign currency exchange rate changes. We calculate constant currency net revenues by translating prior year net revenues in local currency at the average exchange rates applicable for the current period. The translated results are then used to determine year-over-year percentage increases or decreases. We generally refer to such amounts calculated on a constant currency basis as excluding the impact of foreign currency exchange rates. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.... (truncated)These measures may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

About Sotera Health

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

Updates on recent developments in matters relevant to investors can be found on the Investor Relations section of the Sotera Health website at

Investor Relations | Sotera Health. For developments related to EO, updates can be found at

Ethylene Oxide | Sotera Health.⁵

INVESTOR RELATIONS

Jason Peterson

Vice President Investor Relations, Sotera Health

IR@soterahealth.com

MEDIA

Kristin Gibbs

Chief Marketing Officer, Sotera Health kgibbs@soterahealth.com

Source: Sotera Health Company

###⁶

Sotera Health Company

Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)⁷

Sotera Health Company

Segment Data

(in thousands)

(unaudited)

(a) Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities.

(b) Represents share-based compensation expense related to employees and Non-Employee Directors.

(c) Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the Refinancing Term Loans and the Revolving Credit Facility.

(d) Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.

(e) Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with the secondary offerings and shareholder engagement.

(f) Represents litigation and other professional fees associated with our EO sterilization facilities.

(g) Represents (i) the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025 and (ii) the cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on July 23, 2025.

(h) Represents non-cash accretion of asset retirement obligations (“ARO”) related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.⁸

Sotera Health Company

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)⁹

Sotera Health Company

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)¹⁰

Sotera Health Company

Non-GAAP Financial Measures

(in thousands, except per share amounts)

(unaudited)

(a) Represents share-based compensation expense related to employees and Non-Employee Directors.

(b)

Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the Refinancing Term Loans and the Revolving Credit Facility.

(c) Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.

(d) Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with the secondary offerings and shareholder engagement.

(e) Represents litigation and other professional fees associated with our EO sterilization facilities.

(f) Represents (i) the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025 and (ii) the cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on July 23, 2025.

(g) Represents non-cash accretion of ARO related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.

(h) Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities and unusual items from our presentation of adjusted net income.

(i) Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities.

(j)

Represents the difference between the income tax provision as determined under GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (h).

(k)

$28.9 million and $24.4 million of the adjustments for the three months ended June 30, 2026 and 2025, respectively, and $55.2 million and $48.6 million of the adjustments for the six months ended June 30, 2026 and 2025, respectively, are included in cost of revenues, primarily consisting of amortization of intangible assets, depreciation, and accretion of asset retirement obligations.

(l)... (truncated)o have net income in the six months ended June 30, 2025.¹¹

Sotera Health Company

Non-GAAP Financial Measures

($’s in thousands except Net Leverage)

(unaudited)

(a)

Represents Adjusted EBITDA for the twelve months ended June 30, 2026 and December 31, 2025, respectively. Refer to the reconciliation of net income (the most comparable GAAP measure) to Adjusted EBITDA on the following page.¹²

Sotera Health Company

Non-GAAP Financial Measures

(in thousands)

(unaudited)

(a)

Represents share-based compensation expense related to employees and Non-Employee Directors.

(b)

Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the Refinancing Term Loans and the Revolving Credit Facility.

(c)

Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.

(d)

Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting and other fees associated with the secondary offerings and shareholder engagement.

(e)

Represents litigation and other professional fees associated with our EO sterilization facilities.

(f)

Represents (i) the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025 and (ii) the cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on July 23, 2025.

(g)

Represents non-cash accretion of ARO related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.

(h)

Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities and unusual items from our presentation of adjusted net income.

(i)

Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities.

(j)

Represents the difference between the income tax provision as determined under GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (h).

(k)

$106.5 million and $99.9 million of the adjustments for the twelve months ended June 30, 2026 and December 31, 2025, respectively, are included in cost of revenues, primarily consisting of amortization of intangible assets, depreciation, and accretion of asset retirement obligations.¹³

## Financial statements

### Income Statement (Three Months Ended June 30, — (unaudited))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenues: | Service | 278,325 | 257,244 | 519,933 | 481,184 |
| Revenues: | Product | 43,050 | 37,097 | 81,487 | 67,680 |
| Revenues: | Total net revenues | 321,375 | 294,341 | 601,420 | 548,864 |
| Cost of revenues: | Service | 126,840 | 113,293 | 245,668 | 220,922 |
| Cost of revenues: | Product | 16,572 | 14,427 | 30,720 | 25,889 |
| Cost of revenues: | Total cost of revenues | 143,412 | 127,720 | 276,388 | 246,811 |
| Cost of revenues: | Gross profit | 177,963 | 166,621 | 325,032 | 302,053 |
| Cost of revenues: | Selling, general and administrative expenses | 68,156 | 68,893 | 136,367 | 131,954 |
| Cost of revenues: | Amortization of intangible assets | 3,015 | 9,298 | 6,046 | 24,625 |
| Cost of revenues: | Illinois EO litigation settlements |  | 34,000 |  | 64,943 |
| Cost of revenues: | Interest expense, net | 34,405 | 40,651 | 69,150 | 81,527 |
| Cost of revenues: | Loss on refinancing of debt | 936 | 80 | 936 | 80 |
| Cost of revenues: | Foreign exchange (gain) loss, net | -3,746 | 627 | -4,317 | 916 |
| Cost of revenues: | Other income, net | -2,854 | -5,825 | -3,814 | -6,066 |
| Cost of revenues: | Income before income taxes | 78,051 | 18,897 | 120,664 | 4,074 |
| Cost of revenues: | Provision for income taxes | 24,408 | 10,935 | 40,432 | 9,372 |
| Cost of revenues: | Net income (loss) | 53,643 | 7,962 | 80,232 | -5,298 |
| Earnings (Loss) per share: | Basic | 0.19 | 0.03 | 0.28 | -0.02 |
| Earnings (Loss) per share: | Diluted | 0.19 | 0.03 | 0.28 | -0.02 |
| Weighted average number of common shares outstanding: | Basic | 285,773 | 283,933 | 285,333 | 283,747 |
| Weighted average number of common shares outstanding: | Diluted | 288,148 | 285,756 | 287,915 | 283,747 |

### Income Statement (Three Months Ended June 30, — (unaudited))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Segment revenues: | Sterigenics | 211,571 | 194,839 | 397,706 | 364,523 |
| Segment revenues: | Nordion | 49,149 | 42,431 | 91,158 | 74,988 |
| Segment revenues: | Nelson Labs | 60,655 | 57,071 | 112,556 | 109,353 |
| Segment revenues: | Total net revenues | 321,375 | 294,341 | 601,420 | 548,864 |
| Segment income: | Sterigenics | 118,125 | 107,745 | 214,539 | 195,749 |
| Segment income: | Nordion | 27,980 | 23,477 | 51,691 | 40,899 |
| Segment income: | Nelson Labs | 19,634 | 19,513 | 34,162 | 35,926 |
| Segment income: | Total segment income | 165,739 | 150,735 | 300,392 | 272,574 |
| Less adjustments: | Interest expense, net | 34,405 | 40,651 | 69,150 | 81,527 |
| Less adjustments: | Depreciation and amortization(a) | 33,328 | 34,948 | 64,072 | 75,682 |
| Less adjustments: | Share-based compensation(b) | 7,383 | 8,149 | 21,825 | 15,418 |
| Less adjustments: | Loss on refinancing of debt(c) | 936 | 80 | 936 | 80 |
| Less adjustments: | Gain on foreign currency and derivatives not designated as hedging instruments, net(d) | -4,270 | -3,018 | -3,646 | -1,127 |
| Less adjustments: | Business optimization expenses(e) | 1,923 | 2,430 | 2,880 | 4,477 |
| Less adjustments: | Professional services relating to EO sterilization facilities(f) | 13,349 | 14,035 | 23,204 | 26,363 |
| Less adjustments: | Illinois EO litigation settlements(g) |  | 34,000 |  | 64,943 |
| Less adjustments: | Accretion of asset retirement obligation(h) | 634 | 563 | 1,307 | 1,137 |
| Less adjustments: | Consolidated income before income taxes | 78,051 | 18,897 | 120,664 | 4,074 |

### Income Statement (Three Months Ended June 30, — (unaudited))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Net income (loss) |  | 53,643 |  | 7,962 |  | 80,232 |  | -5,298 |
| Amortization of intangible assets | 5,563 |  | 11,924 |  | 11,165 |  | 30,598 |  |
| Share-based compensation(a) | 7,383 |  | 8,149 |  | 21,825 |  | 15,418 |  |
| Loss on refinancing of debt(b) | 936 |  | 80 |  | 936 |  | 80 |  |
| Gain on foreign currency and derivatives not designated as hedging instruments, net(c) | -4,270 |  | -3,018 |  | -3,646 |  | -1,127 |  |
| Business optimization expenses(d) | 1,923 |  | 2,430 |  | 2,880 |  | 4,477 |  |
| Professional services relating to EO sterilization facilities(e) | 13,349 |  | 14,035 |  | 23,204 |  | 26,363 |  |
| Illinois EO litigation settlements(f) |  |  | 34,000 |  |  |  | 64,943 |  |
| Accretion of asset retirement obligation(g) | 634 |  | 563 |  | 1,307 |  | 1,137 |  |
| Income tax benefit associated with pre-tax adjustments(h) | -5,200 |  | -20,063 |  | -11,576 |  | -41,485 |  |
| Adjusted Net Income | 73,961 |  | 56,062 |  | 126,327 |  | 95,106 |  |
| Interest expense, net | 34,405 |  | 40,651 |  | 69,150 |  | 81,527 |  |
| Depreciation(i) | 27,765 |  | 23,024 |  | 52,907 |  | 45,084 |  |
| Income tax provision applicable to Adjusted Net Income(j) | 29,608 |  | 30,998 |  | 52,008 |  | 50,857 |  |
| Adjusted EBITDA(k) |  | 165,739 |  | 150,735 |  | 300,392 |  | 272,574 |
| Net Revenues |  | 321,375 |  | 294,341 |  | 601,420 |  | 548,864 |
| Adjusted EBITDA Margin | 51.6 | % | 51.2 | % | 49.9 | % | 49.7 | % |
| Weighted average number of shares outstanding | Basic | 285,773 |  | 283,933 |  | 285,333 |  | 283,747 |  |
| Weighted average number of shares outstanding | Diluted(l) | 288,148 |  | 285,756 |  | 287,915 |  | 285,684 |  |
| Earnings (Loss) per share | Basic | 0.19 |  | 0.03 |  | 0.28 |  | -0.02 |  |
| Earnings (Loss) per share | Diluted | 0.19 |  | 0.03 |  | 0.28 |  | -0.02 |  |
| Adjusted earnings per share | Basic | 0.26 |  | 0.2 |  | 0.44 |  | 0.34 |  |
| Adjusted earnings per share | Diluted | 0.26 |  | 0.2 |  | 0.44 |  | 0.33 |  |

### Balance Sheet (As of June 30, — (unaudited))

| | As of June 30, – 2026 | As of December 31, – 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 356,727 | 346,456 |
| Current assets: | Accounts receivable, net | 150,538 | 139,329 |
| Current assets: | Inventories, net | 56,372 | 54,375 |
| Current assets: | Other current assets | 82,821 | 73,250 |
| Current assets: | Total current assets | 646,458 | 613,410 |
| Current assets: | Property, plant, and equipment, net | 1,167,667 | 1,130,564 |
| Current assets: | Operating lease assets | 30,919 | 33,393 |
| Current assets: | Other intangible assets, net | 270,171 | 288,227 |
| Current assets: | Goodwill | 1,091,255 | 1,103,232 |
| Current assets: | Other assets | 100,320 | 94,364 |
| Current assets: | Total assets | 3,306,790 | 3,263,190 |
| Liabilities and equity | Total current liabilities | 231,238 | 249,584 |
| Liabilities and equity | Long-term debt, less current portion | 2,125,534 | 2,126,724 |
| Liabilities and equity | Other noncurrent liabilities | 202,791 | 209,772 |
| Liabilities and equity | Deferred income taxes | 81,579 | 71,075 |
| Liabilities and equity | Total liabilities | 2,641,142 | 2,657,155 |
| Liabilities and equity | Total equity | 665,648 | 606,035 |
| Liabilities and equity | Total liabilities and equity | 3,306,790 | 3,263,190 |

### Cash Flow (Six Months Ended June 30, — (unaudited))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|
| Operating activities: | Net income (loss) | 80,232 | -5,298 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | Non-cash items | 98,732 | 84,361 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | Changes in operating assets and liabilities | -61,034 | 33,874 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | Net cash provided by operating activities | 117,930 | 112,937 |
| Investing activities: | Purchases of property, plant and equipment | -92,615 | -51,147 |
| Investing activities: | Other investing activities | 4,188 | 37 |
| Investing activities: | Net cash used in investing activities | -88,427 | -51,110 |
| Financing activities: | Payments on long-term borrowings | -3,558 | -7,547 |
| Financing activities: | Payments of debt issuance costs | -878 | -2,326 |
| Financing activities: | Shares withheld for employee taxes on equity awards | -9,074 | -3,654 |
| Financing activities: | Other financing activities | -1,674 | -1,493 |
| Financing activities: | Net cash used in financing activities | -15,184 | -15,020 |
| Financing activities: | Effect of exchange rate changes on cash and cash equivalents | -4,048 | 8,600 |
| Financing activities: | Net increase in cash and cash equivalents, including restricted cash | 10,271 | 55,407 |
| Financing activities: | Cash and cash equivalents, including restricted cash, at beginning of period | 346,456 | 278,865 |
| Financing activities: | Cash and cash equivalents, including restricted cash, at end of period | 356,727 | 334,272 |
| Supplemental disclosures of cash flow information: | Cash paid during the period for interest | 85,088 | 102,716 |
| Supplemental disclosures of cash flow information: | Cash paid during the period for income taxes, net of tax refunds received | 24,158 | 32,207 |
| Supplemental disclosures of cash flow information: | Purchases of property, plant and equipment included in accounts payable | 35,397 | 10,307 |
